Actively Recruiting
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Led by Dana-Farber Cancer Institute · Updated on 2026-05-28
40
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying a new community-based protocol review process called DIVERSE to improve inclusion and diversity in clinical trial enrollment, especially for blood cancer and leukemia patients. This research aims to test how feasible, acceptable, and effective this process is by involving patients, community members, and investigators to provide feedback on clinical trials and the review process itself. The study is funded by the National Cancer Institute and the American Society of Clinical Oncology and is based on community-based participatory research principles. The DIVERSE process includes specialized training for participants, who then review clinical trial protocols and provide feedback. Participants will sign confidentiality agreements, complete demographic questionnaires, and engage in both online and in-person or remote training sessions. They will also take part in meetings to discuss their reviews and complete exit interviews or focus groups. Investigator participants will request reviews, complete surveys, and provide feedback on the process. Participation lasts about 18 months, during which enrolled participants will be asked to complete various questionnaires, attend training sessions, review protocols timely, and engage in interviews or focus groups to share their experiences. Researchers will measure outcomes such as the rate of protocol review completion and the acceptability of the intervention. This includes tracking how many participants complete reviews within 35 days and the proportion of positive feedback scores. The study is designed to include adults 18 years and older who speak English and can provide consent.
CONDITIONS
Brief Title
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- English speaking
- Ability to understand and willingness to provide oral consent
- DFCI patient who are in remission from a blood cancer for more than 1 year will be preferred
- Site or Principal investigator who is not a member of the research team (for investigator participants)
You will not qualify if you...
- Adults unable to consent
- Individuals under 18 years old (infants, children, teenagers)
- Prisoners
- Unwilling or unable to maintain confidentiality of reviews and clinical trial materials
- Non-English speakers (as protocols are in English and cannot be translated in time)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person or remote)
Duration - About 18 months
Participants complete confidentiality agreements, demographic questionnaires, training sessions, and provide feedback on clinical trial protocols through meetings and interviews.
Multiple training and feedback sessions conducted in-person or remotely over the course of the study
Trial Site Locations
Total: 1 location
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
A
Andrew Hantel, MD
O
Oldy S Bejarano, MPH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here